ReviewLeukemia2009
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
Review in Leukemia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 89 citations in OpenAlex.
- Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study.American journal of hematology · 2023Trial
- Trial
- SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis.Therapeutic advances in neurological disorders · 2024Article
- Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.Clinical microbiology reviews · 2020Review
- Persistent Mixed Donor Chimerism following Double Umbilical Cord Transplantation in a Patient with T-Cell Prolymphocytic Leukemia.Case reports in hematology · 2019Article
- Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.Journal of neurology · 2018Article
- Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.Journal of neurology · 2018Article
- Practical approach to management of chronic lymphocytic leukemia.Archives of medical science : AMS · 2016Article
- Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy.Frontiers in immunology · 2016Review
- Novel and emerging targeted-based cancer therapy agents and methods.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- New antibody approaches to lymphoma therapy.Journal of hematology & oncology · 2014Review
- Stability of alemtuzumab solutions at room temperature.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2013Article
- The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia.Mediterranean journal of hematology and infectious diseases · 2013Article
- Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use.Therapeutic advances in hematology · 2012Article
- Chronic lymphocytic leukemia: treatment of relapse.Leukemia supplements · 2012Article
- Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.Leukemia · 2012Article
- Treatment options for high-risk chronic lymphocytic leukaemia.Therapeutic advances in hematology · 2011Article
- Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia.Blood cancer journal · 2011Article
- First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.OncoTargets and therapy · 2010Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 10 institutions in 7 countries.
Funding
Abstract
The consensus views of an expert roundtable meeting are presented as updated management guidelines for using alemtuzumab in chronic lymphocytic leukemia. Since the publication of previous management guidelines in 2004, clinical experience with alemtuzumab has grown significantly, especially regarding its efficacy and safety, management of cytomegalovirus (CMV) reactivation, identification of patient subgroups likely to benefit from alemtuzumab therapy and subcutaneous administration of alemtuzumab. The updated recommendations include (1) alemtuzumab monotherapy can be safely used as first-line therapy; (2) suitable patient subgroups for alemtuzumab therapy include elderly patients, patients with 17p deletion, patients with refractory autoimmune cytopenias and patients with profound pancytopenia at baseline due to heavily infiltrated bone marrow; (3) alemtuzumab treatment should be continued for 12 weeks (36 doses) whenever possible, and bone marrow examination may be considered at week 12 to evaluate response; (4) monitoring CMV reactivation by weekly PCR is mandated during therapy; when CMV reactivation becomes symptomatic or viremia increases, alemtuzumab therapy should be interrupted and anti-CMV therapy started; (5) subcutaneous administration is safe, easy to perform and appears equally effective compared with intravenous infusion and (6) our strong recommendation is that alemtuzumab combination therapy and consolidation therapy shall not be used outside carefully controlled clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.